²³⁸Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice

References

• Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, Bunin DI, Blakely EA, Bjornstad KA, Rosen CJ, Shuh DK, Raymond KN. 2010. Biomimetic actinide chelators: An update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-li(1,2-hopo) and 5-lio(me-3,2-hopo). Health Phys 99:401–407.
   PubMed Web of Science ®Google Scholar
• Abergel RJ, Raymond KN. 2011. Multidentate terephthalamidate and hydroxypyridonate ligands: Towards new orally active chelators. Hemoglobin 35:276–290.
   PubMed Web of Science ®Google Scholar
• Ansoborlo E, Amekraz B, Moulin C, Moulin V, Taran F, Bailly T, Burgada R, Henge-Napoli M-H, Jeanson A, Den Auwer C, Bonin L, Moisy P. 2007. Review of actinide decorporation with chelating agents. C R Chimie 10:1010–1019.
   Web of Science ®Google Scholar
• Bhattacharyya MH, Breitenstein BD, Metivier H, Muggenburg H, Stradling GN, Volf V. 1992. Guidebook for the treatment of accidental internal radionuclide contamination of workers. Kent, UK: Nuclear Technology Publishing; 41(1).
   Google Scholar
• Bunin DI, Chang PY, Doppalapudi RS, Riccio ES, An DD, Jarvis EE, Kullgren B, Abergel RJ. 2013. Efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: Towards a safe and effective human dosing regimen. Rad Res 179:171–182.
   PubMed Web of Science ®Google Scholar
• Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. 2008. Medical countermeasures against nuclear threats: Radionuclide decorporation agents. Rad Res 170: 540–548.
   PubMed Web of Science ®Google Scholar
• Chang PY, Bunin DI, Gow J, Swezey R, Shinn W, Shuh DK, Abergel RJ. 2012. Analytical methods for the bioavailability evaluation of hydroxypyridinonate actinide decorporation agents in pre-clinical pharmacokinetic studies. J Chromatograph Separat Techniq S4. doi:10.4172/2157-7064.S4-002.
   Google Scholar
• Durbin PW. 2006. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, editors. The chemistry of the actinide and transactinide elements. Netherlands: Springer.
   Google Scholar
• Durbin PW. 2008. Taylor lecture: The quest for therapeutic actinide chelators. Health Phys 95:465–492.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Jeung N, Kullgren B, Clemons GK. 1992. Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 63:427–442.
   PubMed Web of Science ®Google Scholar
• Durbin PW, Jeung N, Rodgers SJ, Turowski PN, Weitl FL, White DL, Raymond KN. 1989. Removal of 238Pu(IV) from mice by polycatechoylate, -hydroxamate or -hydroxypyridinonate ligands. Radiat Prot Dosim 26:351–358.
   Web of Science ®Google Scholar
• Durbin PW, Kullgren B, Xu J, Raymond KN. 2000. Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: Comparative efficacy and toxicity in mouse of ligands containing 1,2-hopo or me-3,2-hopo. Int J Radiat Biol 76:199–214.
   PubMed Web of Science ®Google Scholar
• Fisher DR. 2000. Decorporation: Officially a word. Health Phys 78: 563–565.
   PubMedGoogle Scholar
• Fritsch P, Serandour AL, Gremy O, Phan G, Tsapis N, Fattal E, Benech H, Deverre JH, Poncy J-L. 2010. Structure of a single model to describe plutonium and americium decorporation by dtpa treatments. Health Phys 99:553–559.
   PubMed Web of Science ®Google Scholar
• Gorden AEV, Xu J, Raymond KN, Durbin PW. 2003. The rational design of sequestering agents for plutonium and other actinide elements. Chem Rev 103:4207–4282.
   PubMed Web of Science ®Google Scholar
• Hafer N, Cassatt DR, DiCarlo AL, Ramakrishnan N, Kaminski JM, Norman MK, Maidment BW, Hatchett RJ. 2010. NIAID/NIH radiation/nuclear medical countermeasures product research and development program. Health Phys 98:903–905.
   PubMed Web of Science ®Google Scholar
• Jarvis EE, An DD, Kullgren B, Abergel RJ. 2012. Significance of single variables in defining adequate animal models to assess the efficacy of new radionuclide decorporation agents: Using the contamination dose as an example. Drug Dev Res 73:281–289.
   Web of Science ®Google Scholar
• Kullgren B, Jarvis EE, An DD, Abergel RJ. 2013. Actinide chelation: Biodistribution and in vivo complex stability of the targeted metal ions. Toxicol Mech Methods 21:18–26.
   Google Scholar
• Leggett RW. 2003. Reliability of the ICRP's dose coefficients for members of the public. III. Plutonium as a case of study of uncertainties in the systemic biokinetics of radionuclides. Radiat Prot Dosim 106:103–120.
   PubMed Web of Science ®Google Scholar
• Mordenti J. 1986. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75:1028–1040.
   PubMed Web of Science ®Google Scholar
• National Council on Radiation Protection and Measurements (NCRP). 2008. Management of persons contaminated with radionuclides: Handbook. Bethesda, MD: NCRP Publications.
   Google Scholar
• Radiation Emergency Assistance Center/Training Site (REAC/TS). 1981. Update on chelation therapy: Chelators should not be used for uranium or neptunium. Oak Ridge, TN: REAC/TS Newsletter.
   Google Scholar
• Stradling GN, Henge-Napoli MH, Paquet F, Poncy J-L, Fritsch P, Taylor DM. 2000a. Approaches for experimental evaluation of chelating agents. Radiat Prot Dosim 87:19–27.
   Web of Science ®Google Scholar
• Stradling GN, Henge-Napoli MH, Paquet F, Poncy J-L, Fritsch P, Taylor DM. 2000b. Optimum treatment regimens with animals. Radiat Prot Dosim 87:29–40.
   Google Scholar
• U.S. Food and Drug Administration (FDA). 2004. Guidance for industry: Calcium DTPA and zinc DTPA drug products – submitting a new drug application. Washington, DC: U.S. FDA.
   Google Scholar
• U.S. Food and Drug Administration (FDA). 2006. Guidance for industry: Internal radioactive contamination – development of decorporation agents. Washington, DC: U.S. FDA.
   Google Scholar
• U.S. Food and Drug Administration. (FDA). 2009. Guidance for industry: Animal models – essential elements to address efficacy under the animal rule. Washington, DC: U.S. FDA.
   Google Scholar
• U.S. Food and Drug Administration (FDA). 2010. Approval of new drugs when human efficacy studies are not ethical or feasible. Washington, DC: U.S. FDA.
   Google Scholar
• Wood R, Sharp C, Gourmelon P, Le Guen B, Stradling GN, Taylor DM, Henge-Napoli MH. 2000. Decorporation treatment – medical overview. Radiat Prot Dosim 87:51–57.
   Web of Science ®Google Scholar